中文名稱:巴格列酮 | 英文名稱:Balaglitazone |
CAS:199113-98-9 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.74% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): TQ0272 |
名稱 | Balaglitazone |
描述 | Balaglitazone is a selective peroxisome proliferator-activated receptor (PPARγ) partial agonist with an EC50 value of 1.351 μM for human PPARγ.Balaglitazone can be used as a supplement to insulin therapy, regulates blood glucose, and can be used in studies of heart failure and myocardial infarction. |
細(xì)胞實(shí)驗(yàn) | MTT assay is used for cell viability analyses. Briefly, K562 and K562/DOX cells are seeded in a 96-well plate in RPMI-1640 medium supplemented with 10% FBS at the density of 2 × 104 cells/well. After 24 h incubation, various concentrations of doxorubicin (DOX) with or without balaglitazone are diluted in RPMI-1640 medium (without FBS) and added into each well. Experiments for each group are performed in triplicates and with a blank control. After 48 h of treatment, the medium is removed and 200 μL of RPMI-1640 medium supplemented with 10% FBS and 10% MTT (5 mg/mL) is added. After incubation for another 4 h, the reduced intracellular formazan product is dissolved by replacing 100 μL of RPMI-1640 medium with the same volume of dimethyl sulfoxide (DMSO). Absorbance values are measured at 570 nm with a microplate reader. The half-maximal inhibitory concentration (IC50) of each experiment is calculated. The resistance fold (RF) is calculated by dividing the IC50 value of treatment in resistant cells by the IC50 value of treatment in corresponding parental cells [2]. |
動(dòng)物實(shí)驗(yàn) | Antihyperglycaemic effects of balaglitazone and rosiglitazone are assessed in adult male diabetic db/db mice. At 14 weeks of age, animals are randomized according to fasting blood glucose into 11 groups (n = 6). Mice are dosed orally once daily for 9 days with vehicle (0.2% carboxymethyl cellulose (CMC) + 0.4% Tween-80 in saline) or increasing doses of either balaglitazone (0.1; 0.3; 1.0; 3.0; 10.0 mg/kg/day) or rosiglitazone (0.2; 0.6; 2.0; 6.0 mg/kg/day). After 7 days of treatment, plasma samples obtained in the morning (between 8:00 and 10:00 AM) are analyzed for glucose and insulin. After 9 days of treatment, animals are exposed to an oral glucose tolerance test (OGTT; 3.0 g/kg). The resulting area under the curve is calculated for each of the doses [1]. |
體外活性 | Balaglitazone在 K562 和 K562/DOX 細(xì)胞中表現(xiàn)出相等的細(xì)胞毒性,其 IC50 分別為 0.117 μM和 0.53 μM,并能降低 Doxorubicin 對(duì)這些細(xì)胞的細(xì)胞毒性[2]。 |
體內(nèi)活性 | Balaglitazone 在雄性飲食誘導(dǎo)性肥胖大鼠中(口服10 mg/kg)抑制總體血糖,降低胰島素水平,并增加體重,其效果與口服30 mg/kg吡格列酮相當(dāng)[3]。 |
存儲(chǔ)條件 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 80 mg/mL (202.31 mM), Sonication is recommended. |
關(guān)鍵字 | Balaglitazone |
相關(guān)產(chǎn)品 | Daidzein | 2,3-Butanediol | Naringenin |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥1800 |
VIP9年
|
湖北威德利化學(xué)試劑有限公司
|
2025-01-17 | |
¥900 |
VIP3年
|
成都佰洋科技有限責(zé)任公司
|
2025-01-17 | |
詢價(jià) |
VIP3年
|
江西瑞威爾生物科技有限公司
|
2024-11-29 | |
¥2222.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2024-10-31 |